Promising Results of Personalized Cancer Vaccin...

By Rene Pretorius

February 10, 2025

A phase I clinical trial evaluating a personalized cancer vaccine has demonstrated promising outcomes for patients with high-risk, fully resected clear cell

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.